How personal loss and hope drove Elaine Maynard’s work in clinical trials and patient-centric technologies

Citius Pharma receives FDA approval for immunotherapy targeting rare blood cancer

Halda Therapeutics raises $126M to take 'hold and kill' precision cancer drugs to the clinic

Gilead gains accelerated FDA approval for rare liver disease treatment

FDA lifts hold on BioNTech and MediLink's ADC trial After safety revisions

Breakthrough delivery system could transform Alzheimer’s treatment

First bispecific CAR-T therapy for MS receives green light from FDA to start phase 1

Breaking News: Lecanemab approved in UK but unavailable on NHS

Highlights

array(40) {
  [0]=>
  string(4) "4375"
  ["article_id"]=>
  string(4) "4375"
  [1]=>
  string(93) "Hansoh Pharma, Atomwise launch AI drug discovery collaboration for multiple therapeutic areas"
  ["article_title"]=>
  string(93) "Hansoh Pharma, Atomwise launch AI drug discovery collaboration for multiple therapeutic areas"
  [2]=>
  string(150) "Scientific teams from Atomwise and Hansoh Pharma will work closely together on the programs. The combination of complementary expertise and technologi"
  ["short_description"]=>
  string(150) "Scientific teams from Atomwise and Hansoh Pharma will work closely together on the programs. The combination of complementary expertise and technologi"
  [3]=>
  string(661) "
Scientific teams from Atomwise and Hansoh Pharma will work closely together on the programs. The combination of complementary expertise and technologies has the potential to dramatically increase success 
&#nl
The post Hansoh Pharma, Atomwise launch AI drug discovery collaboration for multiple therapeutic areas appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(661) "
Scientific teams from Atomwise and Hansoh Pharma will work closely together on the programs. The combination of complementary expertise and technologies has the potential to dramatically increase success 
&#nl
The post Hansoh Pharma, Atomwise launch AI drug discovery collaboration for multiple therapeutic areas appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(145) "https://www.pharmaceutical-business-review.com/news/hansoh-pharma-atomwise-launch-ai-drug-discovery-collaboration-for-multiple-therapeutic-areas/"
  ["blog_url"]=>
  string(145) "https://www.pharmaceutical-business-review.com/news/hansoh-pharma-atomwise-launch-ai-drug-discovery-collaboration-for-multiple-therapeutic-areas/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-09-14 14:31:35"
  ["create_at"]=>
  string(19) "2019-09-14 14:31:35"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Hansoh Pharma, Atomwise launch AI drug discovery collaboration for multiple therapeutic ar

Scientific teams from Atomwise and Hansoh Pharma will work closely together on the programs. The combination of compl

array(40) {
  [0]=>
  string(4) "4376"
  ["article_id"]=>
  string(4) "4376"
  [1]=>
  string(93) "Roche’s Tecentriq monotherapy significantly improves OS in phase III lung cancer study"
  ["article_title"]=>
  string(93) "Roche’s Tecentriq monotherapy significantly improves OS in phase III lung cancer study"
  [2]=>
  string(150) "The trial is evaluating Tecentriq as a first-line (initial) monotherapy compared against cisplatin or carboplatin and pemetrexed or gemcitabine (chemo"
  ["short_description"]=>
  string(150) "The trial is evaluating Tecentriq as a first-line (initial) monotherapy compared against cisplatin or carboplatin and pemetrexed or gemcitabine (chemo"
  [3]=>
  string(612) "
The trial is evaluating Tecentriq as a first-line (initial) monotherapy compared against cisplatin or carboplatin and pemetrexed or gemcitabine (chemotherapy) in advanced non-squamous and squamous non-small cell lung 
&#nl
The post Roche’s Tecentriq monotherapy significantly improves OS in phase III lung cancer study appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(612) "
The trial is evaluating Tecentriq as a first-line (initial) monotherapy compared against cisplatin or carboplatin and pemetrexed or gemcitabine (chemotherapy) in advanced non-squamous and squamous non-small cell lung 
&#nl
The post Roche’s Tecentriq monotherapy significantly improves OS in phase III lung cancer study appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(83) "https://www.pharmaceutical-business-review.com/news/roches-tecentriq-lung-cancer-2/"
  ["blog_url"]=>
  string(83) "https://www.pharmaceutical-business-review.com/news/roches-tecentriq-lung-cancer-2/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-09-14 14:31:35"
  ["create_at"]=>
  string(19) "2019-09-14 14:31:35"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Roche’s Tecentriq monotherapy significantly improves OS in phase III lung cancer st

The trial is evaluating Tecentriq as a first-line (initial) monotherapy compared against cisplatin or carboplatin and

array(40) {
  [0]=>
  string(4) "4377"
  ["article_id"]=>
  string(4) "4377"
  [1]=>
  string(81) "Merck initiates phase 3 programme for evobrutinib in relapsing multiple sclerosis"
  ["article_title"]=>
  string(81) "Merck initiates phase 3 programme for evobrutinib in relapsing multiple sclerosis"
  [2]=>
  string(154) "“Evobrutinib is a potential innovation for people living with MS, as it may offer a novel dual mechanism of action that is thought to impact myeloid"
  ["short_description"]=>
  string(154) "“Evobrutinib is a potential innovation for people living with MS, as it may offer a novel dual mechanism of action that is thought to impact myeloid"
  [3]=>
  string(598) "
“Evobrutinib is a potential innovation for people living with MS, as it may offer a novel dual mechanism of action that is thought to impact myeloid cells in 
&#nl
The post Merck initiates phase 3 programme for evobrutinib in relapsing multiple sclerosis appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(598) "
“Evobrutinib is a potential innovation for people living with MS, as it may offer a novel dual mechanism of action that is thought to impact myeloid cells in 
&#nl
The post Merck initiates phase 3 programme for evobrutinib in relapsing multiple sclerosis appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(134) "https://www.pharmaceutical-business-review.com/news/merck-initiates-phase-3-programme-for-evobrutinib-in-relapsing-multiple-sclerosis/"
  ["blog_url"]=>
  string(134) "https://www.pharmaceutical-business-review.com/news/merck-initiates-phase-3-programme-for-evobrutinib-in-relapsing-multiple-sclerosis/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-09-14 14:31:35"
  ["create_at"]=>
  string(19) "2019-09-14 14:31:35"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Merck initiates phase 3 programme for evobrutinib in relapsing multiple sclerosis

“Evobrutinib is a potential innovation for people living with MS, as it may offer a novel dual mechanism of act

array(40) {
  [0]=>
  string(4) "4378"
  ["article_id"]=>
  string(4) "4378"
  [1]=>
  string(93) "Avalon Ventures and COI Pharmaceuticals announce acquisition of Sitari Pharmaceuticals by GSK"
  ["article_title"]=>
  string(93) "Avalon Ventures and COI Pharmaceuticals announce acquisition of Sitari Pharmaceuticals by GSK"
  [2]=>
  string(150) "Sitari has been developing a novel treatment for celiac disease and was the first company formed under the GSK-Avalon venture collaboration in 2013. S"
  ["short_description"]=>
  string(150) "Sitari has been developing a novel treatment for celiac disease and was the first company formed under the GSK-Avalon venture collaboration in 2013. S"
  [3]=>
  string(635) "
Sitari has been developing a novel treatment for celiac disease and was the first company formed under the GSK-Avalon venture collaboration in 2013. Sitari was incubated at COI 
&#nl
The post Avalon Ventures and COI Pharmaceuticals announce acquisition of Sitari Pharmaceuticals by GSK appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(635) "
Sitari has been developing a novel treatment for celiac disease and was the first company formed under the GSK-Avalon venture collaboration in 2013. Sitari was incubated at COI 
&#nl
The post Avalon Ventures and COI Pharmaceuticals announce acquisition of Sitari Pharmaceuticals by GSK appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(146) "https://www.pharmaceutical-business-review.com/news/avalon-ventures-and-coi-pharmaceuticals-announce-acquisition-of-sitari-pharmaceuticals-by-gsk/"
  ["blog_url"]=>
  string(146) "https://www.pharmaceutical-business-review.com/news/avalon-ventures-and-coi-pharmaceuticals-announce-acquisition-of-sitari-pharmaceuticals-by-gsk/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-09-14 14:31:35"
  ["create_at"]=>
  string(19) "2019-09-14 14:31:35"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Avalon Ventures and COI Pharmaceuticals announce acquisition of Sitari Pharmaceuticals by

Sitari has been developing a novel treatment for celiac disease and was the first company formed under the GSK-Avalon

array(40) {
  [0]=>
  string(4) "4379"
  ["article_id"]=>
  string(4) "4379"
  [1]=>
  string(45) "Mallinckrodt to divest BioVectra for £202m"
  ["article_title"]=>
  string(45) "Mallinckrodt to divest BioVectra for £202m"
  [2]=>
  string(156) "The deal includes a fixed consideration of $175m (£141m), comprised of an upfront payment of $135 (£109m) and a long-term note for $40m (£32m), as "
  ["short_description"]=>
  string(156) "The deal includes a fixed consideration of $175m (£141m), comprised of an upfront payment of $135 (£109m) and a long-term note for $40m (£32m), as "
  [3]=>
  string(514) "
The deal includes a fixed consideration of $175m (£141m), comprised of an upfront payment of $135 (£109m) and a long-term note for $40m (£32m), as well as contingent 
&#nl
The post Mallinckrodt to divest BioVectra for £202m appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(514) "
The deal includes a fixed consideration of $175m (£141m), comprised of an upfront payment of $135 (£109m) and a long-term note for $40m (£32m), as well as contingent 
&#nl
The post Mallinckrodt to divest BioVectra for £202m appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(75) "https://www.pharmaceutical-business-review.com/news/mallinckrodt-biovectra/"
  ["blog_url"]=>
  string(75) "https://www.pharmaceutical-business-review.com/news/mallinckrodt-biovectra/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-09-14 14:31:35"
  ["create_at"]=>
  string(19) "2019-09-14 14:31:35"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Mallinckrodt to divest BioVectra for £202m

The deal includes a fixed consideration of $175m (£141m), comprised of an upfront payment of $135 (£109m) and a

array(40) {
  [0]=>
  string(4) "4380"
  ["article_id"]=>
  string(4) "4380"
  [1]=>
  string(80) "FDA approves Xeris’ GVOKE injection for treatment of severe hypoglycaemia"
  ["article_title"]=>
  string(80) "FDA approves Xeris’ GVOKE injection for treatment of severe hypoglycaemia"
  [2]=>
  string(150) "GVOKE is a ready-to-use, room-temperature stable liquid glucagon product, which can be administered to the patient using a prefilled syringe or auto-i"
  ["short_description"]=>
  string(150) "GVOKE is a ready-to-use, room-temperature stable liquid glucagon product, which can be administered to the patient using a prefilled syringe or auto-i"
  [3]=>
  string(579) "
GVOKE is a ready-to-use, room-temperature stable liquid glucagon product, which can be administered to the patient using a prefilled syringe or auto-injector. The liquid glucagon product will be 
&#nl
The post FDA approves Xeris’ GVOKE injection for treatment of severe hypoglycaemia appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(579) "
GVOKE is a ready-to-use, room-temperature stable liquid glucagon product, which can be administered to the patient using a prefilled syringe or auto-injector. The liquid glucagon product will be 
&#nl
The post FDA approves Xeris’ GVOKE injection for treatment of severe hypoglycaemia appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(85) "https://www.pharmaceutical-business-review.com/news/xeris-gvoke-severe-hypoglycaemia/"
  ["blog_url"]=>
  string(85) "https://www.pharmaceutical-business-review.com/news/xeris-gvoke-severe-hypoglycaemia/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-09-14 14:31:35"
  ["create_at"]=>
  string(19) "2019-09-14 14:31:35"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

FDA approves Xeris’ GVOKE injection for treatment of severe hypoglycaemia

GVOKE is a ready-to-use, room-temperature stable liquid glucagon product, which can be administered to the patient us

array(40) {
  [0]=>
  string(4) "4765"
  ["article_id"]=>
  string(4) "4765"
  [1]=>
  string(118) "Incyte announces first patient treated in phase 3 trial program evaluating Ruxolitinib cream in patients with vitiligo"
  ["article_title"]=>
  string(118) "Incyte announces first patient treated in phase 3 trial program evaluating Ruxolitinib cream in patients with vitiligo"
  [2]=>
  string(154) "“Vitiligo is a challenging and life-altering disease further complicated by the lack of effective treatment options available to physicians and thei"
  ["short_description"]=>
  string(154) "“Vitiligo is a challenging and life-altering disease further complicated by the lack of effective treatment options available to physicians and thei"
  [3]=>
  string(714) "
“Vitiligo is a challenging and life-altering disease further complicated by the lack of effective treatment options available to physicians and their patients,” said Jim Lee, M.D., Ph.D., Group 
&#nl
The post Incyte announces first patient treated in phase 3 trial program evaluating Ruxolitinib cream in patients with vitiligo appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(714) "
“Vitiligo is a challenging and life-altering disease further complicated by the lack of effective treatment options available to physicians and their patients,” said Jim Lee, M.D., Ph.D., Group 
&#nl
The post Incyte announces first patient treated in phase 3 trial program evaluating Ruxolitinib cream in patients with vitiligo appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(171) "https://www.pharmaceutical-business-review.com/news/incyte-announces-first-patient-treated-in-phase-3-trial-program-evaluating-ruxolitinib-cream-in-patients-with-vitiligo/"
  ["blog_url"]=>
  string(171) "https://www.pharmaceutical-business-review.com/news/incyte-announces-first-patient-treated-in-phase-3-trial-program-evaluating-ruxolitinib-cream-in-patients-with-vitiligo/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-09-27 14:11:16"
  ["create_at"]=>
  string(19) "2019-09-27 14:11:16"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Incyte announces first patient treated in phase 3 trial program evaluating Ruxolitinib cre

“Vitiligo is a challenging and life-altering disease further complicated by the lack of effective treatment opt

array(40) {
  [0]=>
  string(4) "4766"
  ["article_id"]=>
  string(4) "4766"
  [1]=>
  string(103) "Blade Therapeutics expands anti-fibrotic pipeline with acquisition of ATXCo and its autotaxin inhibitor"
  ["article_title"]=>
  string(103) "Blade Therapeutics expands anti-fibrotic pipeline with acquisition of ATXCo and its autotaxin inhibitor"
  [2]=>
  string(154) "“With the addition of this IND enabled program to our pipeline, we advance our agenda to bring innovative treatments to patients with fibrotic disor"
  ["short_description"]=>
  string(154) "“With the addition of this IND enabled program to our pipeline, we advance our agenda to bring innovative treatments to patients with fibrotic disor"
  [3]=>
  string(674) "
“With the addition of this IND enabled program to our pipeline, we advance our agenda to bring innovative treatments to patients with fibrotic disorders,” stated Wendye Robbins, M.D., 
&#nl
The post Blade Therapeutics expands anti-fibrotic pipeline with acquisition of ATXCo and its autotaxin inhibitor appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(674) "
“With the addition of this IND enabled program to our pipeline, we advance our agenda to bring innovative treatments to patients with fibrotic disorders,” stated Wendye Robbins, M.D., 
&#nl
The post Blade Therapeutics expands anti-fibrotic pipeline with acquisition of ATXCo and its autotaxin inhibitor appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(156) "https://www.pharmaceutical-business-review.com/news/blade-therapeutics-expands-anti-fibrotic-pipeline-with-acquisition-of-atxco-and-its-autotaxin-inhibitor/"
  ["blog_url"]=>
  string(156) "https://www.pharmaceutical-business-review.com/news/blade-therapeutics-expands-anti-fibrotic-pipeline-with-acquisition-of-atxco-and-its-autotaxin-inhibitor/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-09-27 14:11:16"
  ["create_at"]=>
  string(19) "2019-09-27 14:11:16"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Blade Therapeutics expands anti-fibrotic pipeline with acquisition of ATXCo and its autota

“With the addition of this IND enabled program to our pipeline, we advance our agenda to bring innovative treat

array(40) {
  [0]=>
  string(4) "4767"
  ["article_id"]=>
  string(4) "4767"
  [1]=>
  string(95) "Jazz’s JZP-258 investigational medicine meets key end points in phase 3 narcolepsy trial"
  ["article_title"]=>
  string(95) "Jazz’s JZP-258 investigational medicine meets key end points in phase 3 narcolepsy trial"
  [2]=>
  string(150) "The phase 3 global, double-blind, placebo-controlled, randomised-withdrawal, multicentre study has assessed the efficacy and safety of JZP-258 in the "
  ["short_description"]=>
  string(150) "The phase 3 global, double-blind, placebo-controlled, randomised-withdrawal, multicentre study has assessed the efficacy and safety of JZP-258 in the "
  [3]=>
  string(612) "
The phase 3 global, double-blind, placebo-controlled, randomised-withdrawal, multicentre study has assessed the efficacy and safety of JZP-258 in the treatment of cataplexy and excessive daytime sleepiness (EDS) in 
&#nl
The post Jazz’s JZP-258 investigational medicine meets key end points in phase 3 narcolepsy trial appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(612) "
The phase 3 global, double-blind, placebo-controlled, randomised-withdrawal, multicentre study has assessed the efficacy and safety of JZP-258 in the treatment of cataplexy and excessive daytime sleepiness (EDS) in 
&#nl
The post Jazz’s JZP-258 investigational medicine meets key end points in phase 3 narcolepsy trial appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(83) "https://www.pharmaceutical-business-review.com/news/jazzs-jzp-258-narcolepsy-trial/"
  ["blog_url"]=>
  string(83) "https://www.pharmaceutical-business-review.com/news/jazzs-jzp-258-narcolepsy-trial/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-09-27 14:11:16"
  ["create_at"]=>
  string(19) "2019-09-27 14:11:16"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Jazz’s JZP-258 investigational medicine meets key end points in phase 3 narcolepsy

The phase 3 global, double-blind, placebo-controlled, randomised-withdrawal, multicentre study has assessed the effic

array(40) {
  [0]=>
  string(4) "4768"
  ["article_id"]=>
  string(4) "4768"
  [1]=>
  string(142) "Amphivena closes $62m Series C financing to expand clinical development of AMV564 into solid tumors and to develop T Cell engagement portfolio"
  ["article_title"]=>
  string(142) "Amphivena closes $62m Series C financing to expand clinical development of AMV564 into solid tumors and to develop T Cell engagement portfolio"
  [2]=>
  string(150) "The round was co-led by NanoDimension and Qiming Venture Partners USA, and included new investors Clough Capital, Aju IB, Korys Merieux, Kaitai Capita"
  ["short_description"]=>
  string(150) "The round was co-led by NanoDimension and Qiming Venture Partners USA, and included new investors Clough Capital, Aju IB, Korys Merieux, Kaitai Capita"
  [3]=>
  string(749) "
The round was co-led by NanoDimension and Qiming Venture Partners USA, and included new investors Clough Capital, Aju IB, Korys Merieux, Kaitai Capital, Industrial Investors, Nawton Limited and 
&#nl
The post Amphivena closes $62m Series C financing to expand clinical development of AMV564 into solid tumors and to develop T Cell engagement portfolio appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(749) "
The round was co-led by NanoDimension and Qiming Venture Partners USA, and included new investors Clough Capital, Aju IB, Korys Merieux, Kaitai Capital, Industrial Investors, Nawton Limited and 
&#nl
The post Amphivena closes $62m Series C financing to expand clinical development of AMV564 into solid tumors and to develop T Cell engagement portfolio appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(194) "https://www.pharmaceutical-business-review.com/news/amphivena-closes-62m-series-c-financing-to-expand-clinical-development-of-amv564-into-solid-tumors-and-to-develop-t-cell-engagement-portfolio/"
  ["blog_url"]=>
  string(194) "https://www.pharmaceutical-business-review.com/news/amphivena-closes-62m-series-c-financing-to-expand-clinical-development-of-amv564-into-solid-tumors-and-to-develop-t-cell-engagement-portfolio/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-09-27 14:11:16"
  ["create_at"]=>
  string(19) "2019-09-27 14:11:16"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Amphivena closes $62m Series C financing to expand clinical development of AMV564 into sol

The round was co-led by NanoDimension and Qiming Venture Partners USA, and included new investors Clough Capital, Aju

array(40) {
  [0]=>
  string(4) "4769"
  ["article_id"]=>
  string(4) "4769"
  [1]=>
  string(65) "Pfizer expands real-world data collaboration with Flatiron Health"
  ["article_title"]=>
  string(65) "Pfizer expands real-world data collaboration with Flatiron Health"
  [2]=>
  string(150) "As per the agreement terms, Pfizer will tap into the de-identified, real-world datasets and analytical expertise from Flatiron Health to chalk out dev"
  ["short_description"]=>
  string(150) "As per the agreement terms, Pfizer will tap into the de-identified, real-world datasets and analytical expertise from Flatiron Health to chalk out dev"
  [3]=>
  string(570) "
As per the agreement terms, Pfizer will tap into the de-identified, real-world datasets and analytical expertise from Flatiron Health to chalk out development strategies and activities for various 
&#nl
The post Pfizer expands real-world data collaboration with Flatiron Health appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(570) "
As per the agreement terms, Pfizer will tap into the de-identified, real-world datasets and analytical expertise from Flatiron Health to chalk out development strategies and activities for various 
&#nl
The post Pfizer expands real-world data collaboration with Flatiron Health appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(89) "https://www.pharmaceutical-business-review.com/news/pfizer-flatiron-health-collaboration/"
  ["blog_url"]=>
  string(89) "https://www.pharmaceutical-business-review.com/news/pfizer-flatiron-health-collaboration/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-09-27 14:11:16"
  ["create_at"]=>
  string(19) "2019-09-27 14:11:16"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Pfizer expands real-world data collaboration with Flatiron Health

As per the agreement terms, Pfizer will tap into the de-identified, real-world datasets and analytical expertise from

array(40) {
  [0]=>
  string(4) "4770"
  ["article_id"]=>
  string(4) "4770"
  [1]=>
  string(115) "Aldeyra Therapeutics receives fast track designation for ADX-2191 for prevention of proliferative vitreoretinopathy"
  ["article_title"]=>
  string(115) "Aldeyra Therapeutics receives fast track designation for ADX-2191 for prevention of proliferative vitreoretinopathy"
  [2]=>
  string(158) "“Fast track designation is an important milestone for our retinal disease platform, and promising news for PVR patients,” said Todd C. Brady, M.D."
  ["short_description"]=>
  string(158) "“Fast track designation is an important milestone for our retinal disease platform, and promising news for PVR patients,” said Todd C. Brady, M.D."
  [3]=>
  string(699) "
“Fast track designation is an important milestone for our retinal disease platform, and promising news for PVR patients,” said Todd C. Brady, M.D., Ph.D., President and Chief Executive 
&#nl
The post Aldeyra Therapeutics receives fast track designation for ADX-2191 for prevention of proliferative vitreoretinopathy appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(699) "
“Fast track designation is an important milestone for our retinal disease platform, and promising news for PVR patients,” said Todd C. Brady, M.D., Ph.D., President and Chief Executive 
&#nl
The post Aldeyra Therapeutics receives fast track designation for ADX-2191 for prevention of proliferative vitreoretinopathy appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(168) "https://www.pharmaceutical-business-review.com/news/aldeyra-therapeutics-receives-fast-track-designation-for-adx-2191-for-prevention-of-proliferative-vitreoretinopathy/"
  ["blog_url"]=>
  string(168) "https://www.pharmaceutical-business-review.com/news/aldeyra-therapeutics-receives-fast-track-designation-for-adx-2191-for-prevention-of-proliferative-vitreoretinopathy/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-09-27 14:11:16"
  ["create_at"]=>
  string(19) "2019-09-27 14:11:16"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Aldeyra Therapeutics receives fast track designation for ADX-2191 for prevention of prolif

“Fast track designation is an important milestone for our retinal disease platform, and promising news for PVR